• Pro-Pac: Strategic review underway
    Pro-Pac: Strategic review underway
Close×

Revenue at Pro-Pac Packaging for the half year slipped by two per cent, but losses increased to $6.2m as the company faced challenges in its Flexibles business.

Sales were $183.3m, down by $3.8m from $187.1m in the same period in the prior year. Profit before tax sank further into the red, growing by $5.4m from $900,000 last year. Pre-AASB 16 EBITDA also fell into the red, to the tune of $800,000, down by $5.7m from last year.

Flexibles revenue decreased a tad, by one per cent to $143.4m, but its Flexibles EBITDA pre-AASB 16 figure fell from $6m in the black to zero, with EBIT moving from $4.2m in the black to $2.9m in the red, while profit before tax also fell into the red, to a $3.8m loss, from a $2.6m profit last year.

Its Industrial Speciality Packaging division saw revenue fall by 5.5 per cent to $39.9m, but Pro-Pac managed to turn around its losses, scraping over the line into the red in EBITDA pre-AASB 16, EBIT and profit before tax was recorded at $300,000.

John Cerini, CEO and managing director, said: “We have been resolutely focused on delivering our strategy in the face of difficult operating conditions.”

According to Cerini, Pro-Pac has "an increasing pipeline of attractive opportunities" for which the company intends to use its "manufacturing capabilities and expertise" to convert into profitable revenue.

The company says its focus on cost and labour savings will deliver a $10m benefit in the next financial year.

Food & Drink Business

Elixinol Wellness has completed the sale of its US business and reported a narrowed first half loss, with revenue up 5.8 per cent to $7.2 million and gross margin close to 10 per cent higher as the group concentrates on its Australian food and wellness brands.

Nourish Ingredients has completed a 10-tonne industrial production run of its animal-free dairy fat, Creamilux, at SD Guthrie International’s facilities in the Netherlands, under a partnership that gives the Australian company European manufacturing capacity without building its own plant.

Bubs Australia has received permanent regulatory authorisation from the US FDA for its three infant formula products – Bubs Goat, Bubs 365 Day Grass Fed, and Bubs Essential.